MiRNA-29c regulates the expression of inflammatory cytokines in diabetic nephropathy by targeting tristetraprolin

[1]  L. Lanting,et al.  Anti-Inflammatory Role of MicroRNA-146a in the Pathogenesis of Diabetic Nephropathy. , 2016, Journal of the American Society of Nephrology : JASN.

[2]  Wan-Chun Li,et al.  Differential microRNA Profiles Predict Diabetic Nephropathy Progression in Taiwan , 2016, International journal of medical sciences.

[3]  Fan Yao,et al.  5'-Monophosphate-activated protein kinase (AMPK) improves autophagic activity in diabetes and diabetic complications , 2015, Acta pharmaceutica Sinica. B.

[4]  A. Bhatti,et al.  Drug Targets for Oxidative Podocyte Injury in Diabetic Nephropathy , 2015, Cureus.

[5]  Jia Guo,et al.  The Expression of Tristetraprolin and Its Relationship with Urinary Proteins in Patients with Diabetic Nephropathy , 2015, PloS one.

[6]  Yang Qu,et al.  Circulating miR‐145 is associated with plasma high‐sensitivity C‐reactive protein in acute ischemic stroke patients , 2015, Cell biochemistry and function.

[7]  S. Pan,et al.  DNA methyltransferase 3, a target of microRNA-29c, contributes to neuronal proliferation by regulating the expression of brain-derived neurotrophic factor. , 2015, Molecular medicine reports.

[8]  Hai Lin,et al.  Lessons Learned from Whole Exome Sequencing in Multiplex Families Affected by a Complex Genetic Disorder, Intracranial Aneurysm , 2015, PloS one.

[9]  Wei Wei,et al.  Research progress in signalling pathway in diabetic nephropathy , 2015, Diabetes/metabolism research and reviews.

[10]  Yan-ming Sun,et al.  Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[11]  Jinlin Song,et al.  Evaluation of miR-29c inhibits endotheliocyte migration and angiogenesis of human endothelial cells by suppressing the insulin like growth factor 1. , 2015, American journal of translational research.

[12]  Jingqiu Cheng,et al.  Involvement of inflammation-related miR-155 and miR-146a in diabetic nephropathy: implications for glomerular endothelial injury , 2014, BMC Nephrology.

[13]  A. Rubio-Guerra,et al.  Diabetic nephropathy and inflammation. , 2014, World journal of diabetes.

[14]  Jia Guo,et al.  The abnormal expressions of tristetraprolin and the VEGF family in uraemic rats with peritoneal dialysis , 2014, Molecular and Cellular Biochemistry.

[15]  A. Bhansali,et al.  Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting , 2014, Journal of diabetes investigation.

[16]  Jun Zhang,et al.  Urinary miR-29 Correlates with Albuminuria and Carotid Intima-Media Thickness in Type 2 Diabetes Patients , 2013, PloS one.

[17]  L. Tang,et al.  miRNA-29c Suppresses Lung Cancer Cell Adhesion to Extracellular Matrix and Metastasis by Targeting Integrin β1 and Matrix Metalloproteinase2 (MMP2) , 2013, PloS one.

[18]  Simon Lovell,et al.  Phosphorylation of the Leukemic Oncoprotein EVI1 on Serine 196 Modulates DNA Binding, Transcriptional Repression and Transforming Ability , 2013, PloS one.

[19]  Ying Sun,et al.  MiR-29c suppresses invasion and metastasis by targeting TIAM1 in nasopharyngeal carcinoma. , 2013, Cancer letters.

[20]  Yan-ming Sun,et al.  Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. , 2013, Biochemical and biophysical research communications.

[21]  Peiyong Jiang,et al.  Inhibition of miR-29 by TGF-beta-Smad3 Signaling through Dual Mechanisms Promotes Transdifferentiation of Mouse Myoblasts into Myofibroblasts , 2012, PloS one.

[22]  Merlin C. Thomas,et al.  Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. , 2012, Journal of the American Society of Nephrology : JASN.

[23]  Sandhya Sanduja,et al.  The role of tristetraprolin in cancer and inflammation. , 2012, Frontiers in bioscience.

[24]  M. Okusa,et al.  Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. , 2011, American journal of physiology. Renal physiology.

[25]  Youhua Liu.  Cellular and molecular mechanisms of renal fibrosis , 2011, Nature Reviews Nephrology.

[26]  Chun-mei Wang,et al.  miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. , 2011, Biochemical and biophysical research communications.

[27]  Cheuk-Man Yu,et al.  TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. , 2011, Journal of the American Society of Nephrology : JASN.

[28]  J. Long,et al.  MicroRNA-29c Is a Signature MicroRNA under High Glucose Conditions That Targets Sprouty Homolog 1, and Its in Vivo Knockdown Prevents Progression of Diabetic Nephropathy* , 2011, The Journal of Biological Chemistry.

[29]  C. Croce,et al.  microRNAs: Master regulators as potential therapeutics in cancer. , 2011, Annual review of pharmacology and toxicology.

[30]  A. Dick,et al.  Mechanisms of TNFα regulation in uveitis: Focus on RNA-binding proteins , 2010, Progress in Retinal and Eye Research.

[31]  Subbaya Subramanian,et al.  MicroRNAs in Cardiovascular Diseases: Biology and Potential Clinical Applications , 2010, Journal of cardiovascular translational research.

[32]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[33]  Jeffrey E. Thatcher,et al.  Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis , 2008, Proceedings of the National Academy of Sciences.

[34]  Stefanie Dimmeler,et al.  Role of microRNAs in vascular diseases, inflammation, and angiogenesis. , 2008, Cardiovascular research.

[35]  S. Maeda.  Do inflammatory cytokine genes confer susceptibility to diabetic nephropathy? , 2008, Kidney international.

[36]  C. Burge,et al.  The Widespread Impact of Mammalian MicroRNAs on mRNA Repression and Evolution , 2005, Science.

[37]  G. Kollias,et al.  MK2 Targets AU-rich Elements and Regulates Biosynthesis of Tumor Necrosis Factor and Interleukin-6 Independently at Different Post-transcriptional Levels* , 2002, The Journal of Biological Chemistry.

[38]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[39]  P. Blackshear,et al.  Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. , 2000, Blood.

[40]  P. Blackshear,et al.  Feedback Inhibition of Macrophage Tumor Necrosis Factor-α Production by Tristetraprolin , 1998 .

[41]  P. Blackshear,et al.  Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. , 1998, Science.

[42]  R. Zeller,et al.  Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. , 1997, Experimental cell research.

[43]  B. Haynes,et al.  A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. , 1996, Immunity.